Aligos Therapeutics, Inc. (ALGS) Reports Q1 Loss, Misses Revenue Estimates

Stock Information for Aligos Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Aligos Therapeutics Inc.

InflaRx Announces Outcome of Interim Analysis for Vilobelimab Phase 3 Trial in Pyoderma Gangrenosum
InflaRx to Participate in Upcoming Investor Conferences
InflaRx Reports First Quarter 2025 Financial Results and Provides Business Update
InflaRx to Report First Quarter 2025 Results on May 7, 2025
InflaRx Reports Full Year 2024 Results and Highlights Key Achievements and Expected Milestones
InflaRx Showcases Vilobelimab's Role in Immuno-Dermatology at the 2025 AAD Annual Meeting
InflaRx to Showcase Vilobelimab's Role in Immuno-Dermatology at the 2025 AAD Annual Meeting
InflaRx to Report Full Year 2024 Results on March 20 and Announces Participation in March Investor Conferences

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.